# Denosumab

## Prolia inj 60mg

| TAH Drug Code      | [IPRO6](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPRO6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of postmenopausal women w/ osteoporosis at high risk for fracture; bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer; bone loss in men receiving androgen deprivation therapy for prostate cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Dosing             | SC, 60 mg every 6 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypocalcemia. Pregnancy & lactation. Severe renal impairment. Hypersensitivity to any component of the product; facial swelling and urticaria have been reported.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common Endocrine metabolic: Hypercholesterolemia (Osteoporosis, 7.2% ) Gastrointestinal: Constipation (Hypercalcemia of malignancy, 21% ; Glucocorticoid-induced osteoporosis, 2.8% ; giant cell tumor of bone, 10% or greater ), Diarrhea (10% or greater ), Nausea (10% or greater ), Toothache (10% or greater ), Vomiting (10% or greater ) Hematologic: Anemia (Hypercalcemia of malignancy, multiple myeloma, 21% to 22% ; osteoporosis, 3.3% ) Musculoskeletal: Arthralgia (6.7% to 14.3% ), Backache (4.6% to 34.7% ), Musculoskeletal pain (6% to 10% or greater ), Pain in limb (9.9% to 11.7% ) Neurologic: Asthenia (Osteoporosis, postmenopausal, 2.3%; multiple myeloma, bone metastases, breast cancer-related, 13 to 20% ), Headache (3.6% to 24% ) Renal: Cystitis (5.9% ) Respiratory: Cough (10% or greater ), Nasopharyngitis (6.7% to 10% or greater ), Upper respiratory infection (4.9% to 15% ) Other: Fatigue (11% to 25% ) Serious Cardiovascular: Endocarditis (0.08% ) Dermatologic: Cellulitis, Dermatitis, Erysipelas, Rash (2.5% to 5.1% ) Endocrine metabolic: Hypercalcemia, Hypocalcemia (1.7% to 18% ), Hypophosphatemia (Bone metastases, 32%; hypercalcemia of malignancy, 76%; bone metastases, giant cell tumor of bone, multiple myeloma (severe), 9.5% to 21% ) Gastrointestinal: Pancreatitis (0.2% to 0.8% ) Immunologic: Anaphylaxis, Hypersensitivity reaction, Infectious disease, Serious (3.9% to 6% ) Musculoskeletal: Fracture of femur, Atypical (0.9% ), Osteonecrosis of jaw (Up to 6.6% ), Polymyalgia rheumatica, Worsening (2.0% ) Respiratory: Dyspnea (21% to 27% ), Pneumonia Other: Cancer (1.9% to 4.8% ), Substance withdrawal, Rebound effect (3% to 6% ) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Xgeva inj 120mg

| TAH Drug Code      | [IXGE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IXGE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Bone metastases from solid tumors: Prevention of skeletal-related events (eg, fracture, spinal cord compression, bone pain requiring surgery/radiation therapy) in patients with bone metastases from solid tumors. Giant cell tumor of bone: Treatment of giant cell tumor of bone (in adults and skeletally mature adolescents) that is unresectable or where surgical resection is likely to result in severe morbidity. Hypercalcemia of malignancy: Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.                                                                                                                                                                                                        |
| Dosing             | SC, bone metastasis associated with solid tumors 120 mg every 4 weeks. Giant cell tumor of bone, hypercalcemia of malignancy 120 mg every 4 weeks, with additional 120 mg doses on days 8 and 15 of first month of therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity. Severe, symptomatic hypocalcaemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | >10%: Cardiovascular: Hypertension (11%) Central nervous system: Fatigue (Xgeva: <45%), headache (Xgeva: 13% to 24%), peripheral edema (5%; Xgeva: 24%) Dermatologic: Dermatitis (4% to 11%), eczema (4% to 11%), skin rash (3% to 11%) Endocrine & metabolic: Hypophosphatemia (Xgeva: 32%), hypocalcemia (2%; Xgeva: 3% to 18%) Gastrointestinal: Nausea (Xgeva: 31%), decreased appetite (Xgeva: 24%), vomiting (Xgeva: 24%), constipation (Xgeva: 21%), diarrhea (Xgeva: 20%) Hematologic & oncologic: Anemia (Xgeva: 21%) Infection: Influenza (11%) Neuromuscular & skeletal: Weakness (Xgeva: ?45%), arthralgia (7% to 14%), limb pain (10% to 12%), back pain (8% to 12%) Respiratory: Dyspnea (Xgeva: 21% to 27%), cough (Xgeva: 15%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

